This premise has prompted research that aims to understand the p53-MDM2 interaction interface [26][27] to inform the discovery of inhibitors [28][29] in hopes of ultimately preventing tumor development in patients who suffer from cancers arising from hyperactive MDM2 activity. This evidence concerns the gene MDM2 and neoplasm.